阿托伐他汀和厄贝沙坦对血液透析患者营养不良-微炎症综合征的影响  

Effects of atorvastatin and irbesartan on malnutrition-inflammation syndrome in hemodialysis patients

作　　者：姜惠芳[1] 彭兰芬[1] 张月[1] 邵发保[1] 骆九源[1] 郑柳燕[1] 陈少英[1] 李桂兰[1] 

机构地区：[1]东莞市厚街医院,广东东莞523945

出　　处：《海南医学》2010年第11期1-2,9,共3页Hainan Medical Journal

摘　　要：目的探讨阿托伐他汀和厄贝沙坦对血液透析患者营养不良-微炎症综合征的影响。方法 15例血液透析患者应用阿托伐他汀(10mg/d)和厄贝沙坦(150mg/d)治疗,分别于用药前、用药1个月、用药6个月观察血浆白蛋白(ALB)、高敏C-反应蛋白(hs-CRP)和白细胞介素6(IL-6)水平。结果用药6个月后血浆ALB明显上升(P<0.05),用药1个月和用药6个月后血浆hs-CRP和IL-6明显下降(P<0.001)。联合应用常规剂量阿托伐他汀和厄贝沙坦可以明显改善血液透析患者营养不良-微炎症综合征状态。Objective To investigate the effects of atorvastatin and irbesartan on malnutrition-inflammation syndrome in hemodialysis patients.Methods 15 patients with end stage renal disease on regular hemodialysis had been treated with atorvastatin（10mg/d）and irbesartan（150mg/d）for 6 months.The plasma level of albumin（ALB）,high sensitive C-reactive protein（hs-CRP）and interleukin 6（IL-6）were observed before and after 1 month,6 months.Results ALB increased significantly after 6 months of the therapy（P〈0.05）.Hs-CRP and IL-6 decreased significantly after 1 month and 6 months,respectively（P〈0.001）.Conclusion Combined using routine dosage of atorvastatin and irbesartan can improve the malnutrition-inflammation syndrome in hemodialysis patients.

关 键 词：阿托伐他汀 厄贝沙坦 血液透析 营养不良-微炎症综合征 高敏C-反应蛋白 白细胞介素6 

分 类 号：R459.3[医药卫生—治疗学]